The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety

Toxicology

Volumn 181-182, Issue , 2002, Pages 99-102

  Boyd, Ian W ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

ADRAC; Adverse drug reactions; Drug safety; Pharmacovigilance

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; FLUCLOXACILLIN; TIAPROFENIC ACID;

AUSTRALIA; CASE CONTROL STUDY; CYSTITIS; DATA BASE; DRUG MONITORING; DRUG SAFETY; HEALTH PRACTITIONER; HEPATITIS; HUMAN; INTERNATIONAL COOPERATION; POPULATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TIME; WORLD HEALTH ORGANIZATION;

EID: 0037184863     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00262-7     Document Type: Article

References (18)

1. ADRAC, 1980. Mianserin - a possible cause of neutropenia and agranulocytosis. Med. J. Aust. 2, 673-674.
2. ADRAC, 1994. Update on tiaprofenic acid and urinary symptoms. Aust. Adv. Drug React. Bull. 13, 6.
3. ADRAC, 1995. Lodema and the liver. Aust. Adv. Drug React. Bull. 14, 11.
4. ADRAC, 1997. Kombucha tea. Aust. Adv. Drug React. Bull. 16, 6.
5. ADRAC, 1999. Allergic reactions with echinacea. Aust. Adv. Drug React. Bull. 18, 3.
6. ADRAC, 2000. Alert! Interactions with St John's wort. Aust. Adv. Drug React. Bull. 19, 7.
7. ADRAC, 2000. Cyclosporin and St John's wort: CYP3A4. Aust. Adv. Drug React. Bull. 19, 10.
8. Buchbinder R., Forbes A., Kobben F., Boyd I., Snow R.M., McNeil J.J. Clinical features of tiaprofenic acid (Surgam) associated cystitis and a study of risk factors for its development. J. Clin. Epidemiol. 53:2000;1013-1019.
9. Bullock R.J., Rohan A., Straatmans J-A. Fatal royal jelly-induced asthma. Med. J. Aust. 160:1994;44.
10. Day R.O., Mashford M.L. Pharmacotherapeutics: what a difference five decades makes! Med. J. Aust. 174:2001;48-51.
11. Desmond P.V. Flucloxacillin hepatitis - an Australian epidemic. Aust. N.Z. J. Med. 25:1995;195-196.
12. Fairley C.K., McNeil J.J., Desmond P., Smallwood R., Young H., Forbes A., Purcell P., Boyd I. Risk factors for development of flucloxacillin associated jaundice. Br. Med. J. 306:1993;233-235.
13. Henry D.A., Mitchell A.S., Aylward J., Fung M.T., McEwen J., Rohan A. Glucomannan and risk of oesophageal obstruction. Br. Med. J. 292:1986;591-592.
14. Mathew T.H., McEwen J., Rohan A. Urinary incontinence secondary to prazosin. Med. J. Aust. 148:1988;305-306.
15. O'Neill G.F.A. Tiaprofenic acid as a cause of non-bacterial cystitis. Med. J. Aust. 160:1994;123-125.
16. Thomson J.A., Fairley C.K., McNeil J.J., Purcell P. Augmentin-associated jaundice. Med. J. Aust. 160:1994;733-734.
17. Thomson J.A., Fairley C.K., Ugoni A.M., Forbes A.B., Purcell P.M., Desmond P.V., Smallwood R.A., McNeil J.J. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med. J. Aust. 162:1995;638-640.
18. Turner I.B., Eckstein R.P., Riley J.W., Lunzer M.R. Prolonged hepatic cholestasis after flucloxacillin therapy. Med. J. Aust. 151:1989;701-705.